Related Experiment Video
Updated: Jun 28, 2025
05:16
Multiplexed Fluorescent Immunohistochemical Staining of Four Endometrial Immune Cell Types in Recurrent Miscarriage
Published on: August 4, 2021
3.4K
The Combination of circEPSTI1 and MIF Offers Diagnostic Value for Endometrial Cancer
Zhili Cui1, Liyuan Zhou1, Xin An2
1Department of Gynecology, Affiliated Hospital of Hebei University of Engineering, Handan, Hebei, 056002, People's Republic of China.
International Journal of General Medicine
|April 15, 2024
Summary
Endometrial cancer (EC) can be reliably diagnosed using a combination of circEPSTI1 and macrophage migration inhibitory factor (MIF) in patient serum. These biomarkers show elevated levels in EC patients, aiding in early detection and clinical screening.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Discovery
Background:
- Circular RNAs (circRNAs) are stable, uniquely expressed molecules in patient plasma.
- circRNAs show promise as non-invasive biomarkers for various diseases, including endometrial cancer (EC).
- Macrophage migration inhibitory factor (MIF) is also being evaluated as a potential EC biomarker.
Purpose of the Study:
- To identify circRNAs for diagnosing EC in serum samples.
- To evaluate the diagnostic utility of circEPSTI1 and MIF in EC detection.
- To assess the combined diagnostic performance of circEPSTI1 and MIF.
Main Methods:
- Quantified circEPSTI1 and MIF levels in plasma from EC patients and healthy controls (n=186 each) using qPCR and ELISAs.
- Assessed diagnostic accuracy using receiver operating characteristic (ROC) curve analyses.
- Evaluated the combined diagnostic power of both biomarkers.
Main Results:
- EC patients exhibited significantly higher serum levels of circEPSTI1 and MIF compared to healthy individuals.
- circEPSTI1 expression correlated with EC stage, histologic grade, and residual tumor.
- Serum circEPSTI1 achieved an Area Under the Curve (AUC) of 0.835, MIF achieved 0.6646, and their combination yielded an AUC of 0.8604.
Conclusions:
- Elevated circEPSTI1 and MIF in serum are indicative of endometrial cancer.
- The combination of circEPSTI1 and MIF offers a promising approach for reliable EC diagnosis.
- This combined biomarker strategy may enhance clinical screening for endometrial cancer.
